ERFA-AMIKACIN DIN 02489147
Status: Cancelled Post Market
Holder: SEARCHLIGHT PHARMA INC
Molecule: AMIKACIN (AMIKACIN SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | AMIKACIN (AMIKACIN SULFATE) 250 MG |
|---|---|
| Dosage form | Solution |
| Route | Intramuscular; Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01GB06 AMIKACIN |
| Original market date | 29-Nov-2019 |
| Current status date | 22-Nov-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Searchlight Pharma Inc — licence 102247, currently licensed, last inspection rating C (2024-10-10).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMIKACIN (AMIKACIN SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02173336 | AMIGLYDE-V | ZOETIS CANADA INC | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Marketed |
| 02529459 | AMIKACIN SULFATE INJECTION | JAMP PHARMA CORPORATION | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Marketed |
| 02486717 | AMIKACIN SULFATE INJECTION | OMEGA LABORATORIES LIMITED | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Marketed |
| 02242971 | AMIKACIN SULFATE INJECTION USP | SANDOZ CANADA INCORPORATED | Liquid | AMIKACIN (AMIKACIN SULFATE) 250 MG | Marketed |
| 02481073 | AMIKACIN SULFATE INJECTION USP | MARCAN PHARMACEUTICALS INC | Solution | AMIKACIN (AMIKACIN SULFATE) 500 MG | Marketed |
| 02539535 | AMIKACIN SULFATE INJECTION | JUNO PHARMACEUTICALS CORP. | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Cancelled Pre Market |
| 02525909 | AMIKACIN SULFATE INJECTION | HIKMA CANADA LIMITED | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Cancelled Post Market |
| 00397415 | AMIKIN | BRISTOL-MYERS SQUIBB CANADA | Solution | AMIKACIN (AMIKACIN SULFATE) 250 MG | Cancelled Post Market |
| 02506599 | VPI-AMIKACIN | VPI PHARMACEUTICALS INC | Solution | AMIKACIN (AMIKACIN SULFATE) 500 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29202 | 2022-10-14 | Abbreviated New Drug Submission (ANDS) | Administrative: Change in Product Ownership |
| 22230 | 2019-06-03 | Abbreviated New Drug Submission (ANDS) |